Q2 2024 EPS Estimates for Medpace Holdings, Inc. Decreased by William Blair (NASDAQ:MEDP)

Medpace Holdings, Inc. (NASDAQ:MEDP) – William Blair lowered their Q2 2024 EPS estimates for shares of Medpace in a note issued to investors on Tuesday, April 23rd. William Blair analyst M. Smock now forecasts that the company will post earnings per share of $2.43 for the quarter, down from their previous forecast of $2.57. The consensus estimate for Medpace’s current full-year earnings is $11.23 per share. William Blair also issued estimates for Medpace’s Q3 2024 earnings at $2.63 EPS, Q4 2024 earnings at $2.81 EPS, Q2 2025 earnings at $3.04 EPS, Q3 2025 earnings at $3.14 EPS and Q4 2025 earnings at $3.36 EPS.

Several other analysts have also weighed in on the stock. Guggenheim lifted their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $340.00 to $450.00 in a report on Tuesday. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Robert W. Baird boosted their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Up 1.6 %

NASDAQ:MEDP opened at $395.93 on Friday. The company has a fifty day moving average of $397.83 and a 200-day moving average of $325.15. The firm has a market capitalization of $12.27 billion, a P/E ratio of 40.36, a P/E/G ratio of 1.98 and a beta of 1.38. Medpace has a twelve month low of $189.30 and a twelve month high of $421.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same quarter last year, the business earned $2.27 EPS. The company’s revenue was up 17.7% compared to the same quarter last year.

Institutional Investors Weigh In On Medpace

Hedge funds and other institutional investors have recently modified their holdings of the stock. RiverPark Advisors LLC bought a new stake in shares of Medpace during the fourth quarter valued at about $26,000. Contravisory Investment Management Inc. bought a new stake in shares of Medpace during the fourth quarter valued at about $26,000. Rise Advisors LLC bought a new stake in shares of Medpace during the first quarter valued at about $27,000. Mather Group LLC. bought a new stake in shares of Medpace during the first quarter valued at about $28,000. Finally, FinTrust Capital Advisors LLC bought a new stake in shares of Medpace during the third quarter valued at about $30,000. 77.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now directly owns 5,525,959 shares in the company, valued at $2,135,175,298.01. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 over the last three months. 20.30% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.